Page 2 - ஆர்கஸ் உயிர் அறிவியல் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Search jobs 10-Apr-2021 Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting Phase 1/1b results for the etrumadenant combination demonstrated a 4.2 month PFS, approximately double the 2 months reported for current standard of care therapies in the ≥3L mCRC setting ARC-9, a randomized Phase 1b/2 platform study, has been initiated to further evaluate etrumadenant-zimberelimab combinations in the 2L, 3L and ≥3L+ mCRC settings Our novel series of HIF-2α inhibitors, including AB521, a highly-potent molecule with a favorable pharmacokinetic profile, has been described for the first time; we remain on track to initiate clinical development for this program in 2H:21

United statesKatherine bockMichael cecchiniAmerican association for cancer researchYale cancer centerArcus biosciences incArcus biosciencesCancer researchHypoxia inducible factorUpdated resultsMetastatic colorectalBill grossmanChief medical officerAssistant professorMedical oncologySmilow cancer